Market Cap: $8.28B
II
ImmunityBio, Inc.
IBRX
NASDAQ (NASDAQ Global Select)USD
Market Cap: $8.28B
ImmunityBio has secured a critical partnership with Japan's BCG Laboratory to enhance the supply of Bacillus Calmette-Guérin (BCG) in the United States, addressing an urgent need in the treatment of b…
ImmunityBio's recent partnership with Japan's BCG Laboratory represents a vital step in addressing the ongoing shortages of Bacillus Calmette-Guérin (BCG) used in bladder cancer treatments. This agree…
ImmunityBio Strengthens Financial Foundation Amid Class Action Lawsuits ImmunityBio has successfully secured $75 million in non-dilutive financing through a strategic deal with Oberland Capital. This…
ImmunityBio's Breakthrough in Bladder Cancer Treatment ImmunityBio recently celebrates a significant development in oncology with the approval of its immunotherapy drug, Anktiva, in combination with B…
ImmunityBio's Anktiva Approval Enhances Bladder Cancer Treatment Options ImmunityBio announces a major advancement in oncology with the recent approval of Anktiva for use in combination with Bacillus…
ImmunityBio Advances NK Cell Therapy Production ImmunityBio Inc. makes significant strides with its natural killer (NK) cell therapy platform, highlighting a pivotal moment for the company within the…
ImmunityBio Achieves Milestone in NK Cell Therapy Manufacturing ImmunityBio Inc. makes significant strides in the field of immunotherapy with the successful completion of its manufacturing engineering…
ImmunityBio Advances Cancer Therapy Application Amid Calls for More Data ImmunityBio, a pivotal player in the immunotherapy sector based in Culver City, California, makes significant strides in addres…
ImmunityBio Resubmits Application for ANKTIVA in NMIBC Treatment ImmunityBio, a commercial-stage immunotherapy company located in Culver City, California, has taken significant steps forward by resubm…
ImmunityBio Advances Cancer Treatment with New Application Submission ImmunityBio, a California-based immunotherapy company, makes significant progress in the fight against bladder cancer by resubmitt…
ImmunityBio Advances Bladder Cancer Treatment with Innovative Trial ImmunityBio Inc. recently reaches a significant milestone with the completion of patient enrollment in a pivotal randomized trial fo…
ImmunityBio's Strategic Position in Immuno-Oncology Growth ImmunityBio Inc. strategically enhances its focus on the surging immuno-oncology sector, aligning its innovative therapies to meet the escala…
ImmunityBio Advances in Immuno-Oncology with Pivotal Bladder Cancer Trial ImmunityBio Inc. (NASDAQ: IBRX) marks a significant milestone in the field of immuno-oncology with the recent completion of pa…
ImmunityBio Prepares for Q4 Earnings Release Amid Market Speculation ImmunityBio Inc. (NASDAQ: IBRX) stands at a pivotal moment as it approaches the release of its fourth-quarter earnings, scheduled f…
ImmunityBio Reports Positive Growth Ahead of Full Q4 Financial Disclosure ImmunityBio Inc. (NASDAQ: IBRX) announces significant revenue growth, igniting investor enthusiasm in advance of its detailed…
Title: ImmunityBio's Noteworthy Market Movements Prompt Caution Among Investors In the recent premarket session, ImmunityBio Inc. (NASDAQ: IBRX) experiences a notable decline in shares, prompting a wa…
ImmunityBio: Navigating the Landscape of Biopharmaceutical Innovation ImmunityBio Inc. positions itself at the forefront of the biopharmaceutical industry, focusing on developing innovative therapies…
ImmunityBio expands global commercial reach after EU authorization ImmunityBio is rapidly expanding its international commercial footprint after the European Commission grants authorization for its ca…
ImmunityBio expands international commercial footprint with ANKTIVA ImmunityBio is rapidly broadening ANKTIVA’s global reach after securing European Commission authorization and approvals in the Kingd…
ImmunityBio at the Forefront of Cancer Treatment Innovation ImmunityBio is part of a transformative shift in the precision medicine landscape, particularly in the field of immuno-oncology, where the f…
ImmunityBio's Role in the Evolving Landscape of Immuno-Oncology ImmunityBio, a clinical-stage immuno-oncology company, finds itself amidst a transformative era in the precision medicine sector, which…
ImmunityBio's Anktiva Receives EMA Recommendation for Bladder Cancer Treatment ImmunityBio, Inc. is on the cusp of a significant milestone as the European Medicines Agency (EMA) recommends conditional…
ImmunityBio Advances in Immunotherapy Development Amid Market Upturn ImmunityBio, a biotechnology firm focused on immunotherapy, is making significant strides in its clinical research and development…
ImmunityBio's Strategic Advancements in Cancer Immunotherapy ImmunityBio stands at the forefront of innovation in the field of cancer immunotherapy, focusing on harnessing the body's immune system to…
Oncolytics Biotech Advances Cancer Treatment with GOBLET Study Oncolytics Biotech Inc. is at the forefront of innovation in cancer treatment, particularly through its immunotherapy, pelareorep. The co…